Graham H. Jackson
Led Myeloma XI, the 4,000-patient UK trial that proved lenalidomide maintenance extends survival after transplant.
Overview
Graham Jackson was chief investigator of Myeloma XI, the largest myeloma trial ever run, which showed lenalidomide maintenance improves progression-free and overall survival in transplant-eligible patients and defined the benefit of triplet induction, and of the earlier Myeloma IX trial. He chairs the UK Myeloma Research Alliance and leads the RADAR trial of MRD-guided treatment.
Pages like this
not linked directly; found by shared links- CompanyMission Bio
Shares MRD / molecular residual disease testing, Multiple myeloma.
- PersonNikhil C. Munshi
Shares MRD / molecular residual disease testing, Multiple myeloma and the tag myeloma.
- PersonMaría-Victoria Mateos
Shares Multiple myeloma and the tag myeloma.
- PersonPieter Sonneveld
Shares MRD / molecular residual disease testing, Multiple myeloma and the tag myeloma.
- PersonC. Ola Landgren
Shares MRD / molecular residual disease testing, Multiple myeloma and the tag myeloma.
- PersonSigurdur Y. Kristinsson
Shares Multiple myeloma and the tag myeloma.
- PersonPeter Hillmen
Shares MRD / molecular residual disease testing and the tag uk.
- PersonMeletios A. Dimopoulos
Shares Multiple myeloma and the tag myeloma.